<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-022859
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050728
<FILING-DATE>20050728
<DATE-OF-FILING-DATE-CHANGE>20050728
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05979644
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v022534_6k.htm
<TEXT>
<html>
  <head>
    <title></title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of July 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited<br></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                July 28, 2005</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td>
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                  Finlay</font></font></div>
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                  Financial Officer and Company
                  Secretary</em></font></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  becomes founding member of the NASDAQ Health Care
                  Index</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v022534_ex99-1.htm
<TEXT>
<html>
  <head>
    <title></title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="center">
      <table bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="#ffffff">
            <td width="50%">&#160;</td>
            <td width="50%"><img src="logo.jpg" alt="" align="right"></td>
          </tr>
          <tr bgcolor="#ffffff">
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><strong><font size="2">ASX/MEDIA
                RELEASE</font></strong></div>
            </td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong><font size="2">28<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                July 2005</font></font></strong></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      becomes founding member of <br>the NASDAQ Health Care
      Index</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: #000000" align="center" noshade size="2" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
      nanotechnology company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
      NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      pleased to announce that it has been made a founding member of the NASDAQ Health
      Care Index (IXHC).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      NASDAQ Health Care Index is a market value weighted index that contains
      NASDAQ-listed companies classified, according to the FTSE Global Classification
      System, as "Health," "Pharmaceutical" or "Biotechnology." These classifications
      include health maintenance organisations, hospital management and long-term
      care, medical equipment and supplies, other health care, biotechnology, and
      pharmaceutical companies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
      Rezos, Managing Director of pSivida said, &#8220;As one of only 11 Australian
      companies listed on NASDAQ, our inclusion on the Health Care Index is
      recognition of pSivida&#8217;s increased visibility in the United States, the world&#8217;s
      largest health care and financial market&#8221;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      inclusion on the NASDAQ Health Care Index is in addition to its listing on
      the
      Merrill Lynch Nanotechnology Index announced earlier this year on March
      17</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      announcement follows the appointment this week of two US based Non-executive
      Directors to the pSivida Board, Dr. David J Mazzo, President and CEO of Chugai
      Pharma USA and Mr. Michael Rogers, CFO of Indevus Pharmaceuticals Limited.
      </font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
      by:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverley
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 9 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="34%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Swallow, PhD / Helena Podd</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                Dewe Rogerson</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +44 (0)20 7282 2948 / 2867</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
            </td>
          </tr>

      </table>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global nanotechnology company committed to the biomedical sector and the
      development of products in healthcare. The company&#8217;s focus is the development
      and commercialisation of a modified form of silicon (porosified or
      nano-structured silicon) known as BioSilicon&#8482;. As a new and exciting
      biocompatible material, BioSilicon&#8482; offers multiple potential applications
      across the high growth healthcare sector, including controlled release drug
      delivery, targeted cancer therapies (including brachytherapy and localized
      chemotherapy), tissue engineering and orthopedics. Potential diagnostics
      applications are being developed through its subsidiary AION Diagnostics
      Limited. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
      animals. The IP portfolio consists of 26 patent families, 29 granted patents
      and
      over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
      biomaterial was granted in the UK in 2000 and in the US in 2001. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and in
      Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
      Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
      largest science and technology company in Europe. QinetiQ is the former UK
      government Defence Evaluation Research Agency and was instrumental in
      discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
      having access to its cutting edge research and development facilities. For
      more
      information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.qinetiq.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial">This
      document contains forward-looking statements that involve risks and
      uncertainties. Although we believe that the expectations reflected in such
      forward-looking statements are reasonable at this time, we can give no assurance
      that such expectations will prove to be correct. Given these uncertainties,
      readers are cautioned not to place undue reliance on such forward-looking
      statements. Actual results could differ materially from those anticipated in
      these forward-looking statements due to many important factors including: our
      failure to develop applications for BioSilicon<sup>TM</sup> due to regulatory,
      scientific or other issues. Other reasons are contained in cautionary statements
      in the Registration Statement on Form 20-F filed with the U.S. Securities and
      Exchange Commission, including, without limitation, under Item&#160;3.D,
      "Risk
      Factors" therein. We do not undertake to update any oral or written
      forward-looking statements that may be made by or on behalf of
      pSivida.</font></div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````4```_^X`#D%D
M;V)E`&3``````?_;`(0``@("`@("`@("`@,"`@(#!`,"`@,$!00$!`0$!08%
M!04%!04&!@<'"`<'!@D)"@H)"0P,#`P,#`P,#`P,#`P,#`$#`P,%!`4)!@8)
M#0L)"PT/#@X.#@\/#`P,#`P/#PP,#`P,#`\,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`.@#-`P$1``(1`0,1`?_$`+H``0`#``(#`0``````
M```````&!P@%"0,$"@$!`0`"`@,!```````````````$!0,&`@<(`1```0,#
M`@0#!0,'!PT``````0(#!!$%!@`'(1(3"#%!%%%A(C()4C,5<;%"<B,6-H%B
M@G.S)'61H<'2-)2T-;5V%S<X$0`!`P($`@<$!@@&`P`````!``(#$00A,1(%
M409!87&!(A,'H;'1,I'!4G(S%/#A\4*"DK(C8L)S-!4UHA87_]H`#`,!``(1
M`Q$`/P#O\T1-$31$T1-$31%1FYO<)@&V<^+C3KDS,-P;G1-FVXQIDW"\2%*^
M4K90:,H)\5NJ2/,5UD;&78]"K+W=H;8Z,72')K<7?J[U!XT'NLW'!GS[_C_;
MW8GQS0K'`AMY+?P@\1ZJ3)*(3:O"H;;73B*ZY?VV]?L44,W*YQ+FPMX`:W]Y
M/A^A<1VZYONG/W.WQVOSG*&MQ;)MA*MT>TY[Z%BWR%R)C)><AO-10&E*;'B0
M*@CC\P`^RM;0$"E5CV>YN77$T$KM8C(HZ@&?1AA^Q;"U@6PIHB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(O4GR5PH4J6W%=FKC-*<1#8%7'2D5Y$`^)
M/@-1+^Y=;6[Y6L=(6M)#6XN=0?*WK/0N31J(%:*"V[<FTR;E&M%VMUPQN?,X
M0V[DT&T.$F@2%A1H2>'&FM(V[U&LIKIEI=12VLK_`)1,W2'=%`ZIQKAC3'#-
M27VC@W4TAP'!<_D>5V[%T15W!B8\F65ALQ&%/\O3H3S\OR_-PKJ^YBYIM=C#
M#<-D<'UIH87TTTKJIEGAQQX+%%`Z6M**$_\`FO"?M3_]V/\`K:TG_P"T\O\`
M&7^3]:D_\=+U*$Y>-P-X76;'M[N([MEB@;0K)KHQ:7#?7VEDU1`F/.=!BH%.
M8-J6*U!\M;IRUSC8[X7"W9)X0#5["QI!RH>E4NY[?=NHUD@8TYTQ?W'(>]?F
M#XSM)L8[,QK;[%IEXR:55W)+RT#/NTQPFJESI[RN=:B34I!Y03P2-5F]^HEG
M9W9LHHY+B=HJYD+=6C[QJ!7*H%2*T.*S[=L<5LRK`&US<[YG=I_0*4;C[F7J
MQXO:H>(V%R7NEG9<@X)B<T<I;D#[V;.Y:].+$0>JZKV<J!\:TC6V[/=NOK9D
M[XWQ:A4L>*/;B10CB<U&W.Y=;C1%1TCL&CH^\?\`"W,_1TKD-EMI[?L_A3>.
M,W!V^WRYRW[SF>42/O[I>)I"Y4I?L"E"B4^20!Q-29\C]1JN.VV#;.+0#5Q-
M7'[3CF5;>N"GIHB:(H_=\KQRPK2U=[S&@O*%0PM=7*'SY$U53WTU0;MS3M>T
MN#;NX9&X_ND^+^45=3KHLL<#Y/E!*6?*L=OZE-V>\1ISJ.*F$+HY3V\BJ*I[
MZ:^[1S1M>[$MM+ADCAT`^+^4T=3KHDD#X_F%%SKCB6FW'5_(VDJ53V`5.KN2
M01M+CD!7Z%C`JH9C.X&.Y9,?@6AR0J1'9+[@=9+8Y`H)X$^=5#6F\M<_[7S!
M.Z"T+R]K=1U-TBE0,^TA2)K5\0JY3;6ZJ,FB*.Y=E%JPG%\@S"^*=19L9M\B
MYW1;#9=<#$9LN.%"!Q4>5)H-?6BIHL-Q.V"-TC\F@D]@54[*]QNVN_JLB1M[
M(N3ZL7$55U]?#7$H)G5Z7)S$\WW*J^S7.2)S,U`VW>;?<"X0D^&E:CC7X*^-
M8U:J&9MN)@VW$")=,\RFW8I;ITCTL.9<G@RVX]RJ7TTE7B>5)-/=KDUI=DHU
MS>0VS0Z5P:#ABN4Q?*L<S6QPLEQ.\Q<@L%RZGH+O"<#K#O2<4TOD6.!Y5H*3
M[QKX00:%9()XYV!\9#FGI"Y_7Q94T1-$31$T19>W9MS"9=WDM--M/,OLO=1M
MJ(VLE:4@DN)?ZZN*J\6_'W<=>8?5?;XVSSRM`#FN:ZH;"TX@5J\2><[.N,6?
M4*JZL7&@'Q^%/:K$N.[>)81A&'Y%F]Y1;W<D7`MELC<7),Z?*4AE+;#0^)9*
ME<RB."14D@:[_P"4+V3<MIM9WXO?$TN/72A/>50;E=0V;CK-`74'$D]`"RG<
MTE%SN*#0%$QY)`\.#BAKPON7^[E^^[WE;@WY0MY2I1@6&1-0!6%`6\@>56VB
MH?FU[QNKHVFW/F'[D1=_*VOU+6`W4^G$K,6VD-$V=#GRD(DR9=S2XXMUF&Z:
MI4%$A3KZ7DDDDGE;/M%=>9?3:S;<W,<\H#GOF!)<V%YP(-:OD;*TUJ3IC/$5
M*N;QVEI`X=?PI[5IJ)8+=%N\^_\`2Z]YN+:([UQ=^)Q$9LE3<=O[#8)*N4>*
MB5&IUZQKT+7FQ-#B_I/3U<.Q<UKXLBS;F/=;M%@FZ47:#(IMRBY=+D6^,E28
M:E0D*N006%.22H)2D!P%:CP3QKX:RMA<YNH*FN=^M;>X%N\D/J!EAXJ4Q[U6
MUZ^H)VWV;(WL?%\NUV9C/^GDY';K>I^W)4#RJ4ESG2XXD'])MM0/BFNN0MGD
M54*7FVPCDT:B>L##X_0%KM.0V^X8N<IL,QF[6R5;#<K3.84%M2&E-=5I:%#Q
M"A0ZJMVNG6=I-,T5=&QS@.MK2:>Q;-`YLVDM-6NI0]162L$L<;.LJ>9R"XNI
M5(:=F/K2L!Z0[S#X4J4#]HGP\!KQYR-LD7->\N9N$SO$USR:@/D=4>$$UXEV
M60PZMBN9#!'X!U*:W[:3(+/?X$C"5.OL??,RW74-KBNMD<%+/+S`^(H/:#K=
M=\])=RVW<HI-D+G,^8.<YK71.:>DX5!Z*#B".,:*_8]A$G[5I!DO_A;:KJE`
MD^E!N*&B2CGY/V@0>!I6M->C83)^3!N@->C^X&Y5IX].6%:T50::O#QP57[>
M2]N)%VF(PZWOQ+@(A,EQT/`%GG14?M%J'S4UU?Z?7?*LM[(-GB<R7RSJ)U_)
MJ;AXG.'S:5-NVSAH\PX54$F]VVT5MW:3LK<'[S"S==W8LB&GK>M,4R9(26"'
M^:G(X%IY54\QKN00N+=70M6=O]JVY_+$D/K3+"IR5A;Q;U8+L7C<+*L^E2X]
MLN%P;MD1,*.J2\M]QMQT4;20>4):42?+A[=<61EYH%*W'<H;",22G`FF''$_
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MPYT%2:\*UX:EV\;F.-5IG-.[6]_:,,+L0_$'`C`]"W#V+_\`RWMA^K=?^JS-
M1[G\0K:.5?\`K8OXOZBO'N7WO;!;87^9C%ROL[([W;5J:ND2P1?6(C.I-%-.
M/K6TUSI\TI62/`T/#1EN]PJOM[S/96CRQSBYPSTBM/<%)MG>[+9?>^ZN8]B%
M\DP\E2TIYG'KQ',.2^V@56ICXEMN\HXD)65`<:4XZXOA<S-9MNW^TOW:(W>+
M@<#\%I36)72:(FB*C=TK2AY<I8?8:];%27"\_"8#:D*"4K7U&5/%)-`2%@>7
M#72WJAL+YF/F%`Q[0"YSH6-:\?+J<Z,R&M!E(.&"L+*8`AO3G3&M/I^I57@V
M.[5W'-+'GN:.A[.,*M8LF,)N+_4MD1I+SKAEPVS5I+ZPX$*76M$@I\SKAZ:^
MH>W0[8S;KR9D4L-6U)&A[:G26O\`EPRSZ*C!0[_9&R7?YJA<:4'!O6!Q/%5S
M/4E<^:M"@I"Y+JDK'$$%PD$'7F+<'AUU(YIJ"]V/>5L[/E"U%G&XF/,8M*M5
MKN;-QNMRB^D;;CJ"TMAQ(0M2UCX10$^=:Z]1<[^H>UQ;.^UMIFR3RQ^6`PU#
M=0TN+G?**`GIK7JJ52VUH\R!Q%`#5<5M5CSB?1R26I$:`7%N2V'H<AE3RO!`
M(8+H("J_><"/Y-57I9R^]OER'2YD>HES70R,+SDW"/S00#7\7`C@:+G?2UJ.
M/:/KI[%?^N_%5IHBZ#>]6%&N?>1*MLUOK0KB[B\68U4IYVGF8[;B:BA%4J(J
M-64!I&NI^96!^[:3D=/N"TO]0?9K;+"MGL*OV&X7:L5N-HR&/:&GK7&;C%V'
M(B2%J;?*`"Z0IA!"EDD<>/$ZQ6LCBXU*NN<-MMX+1CXV!I#J8"F%#GQR6F.Q
M"XOW7M?P%N8>L+>Y=(#7-QJRU/?"$GW!)Y?R:P7;`7$$5!5YRI(7[=&3T5'M
M*DV7[/W2W2G;MAZE28R5]9%O2KDDL*K7]DJHY@/+CS?EUY?YO](+RSF-WLY+
MFUU!@-)&'/P']X#HQ#AEXLUO=O?M<-,GT]"\.)[OWFT2D6O+T.3(B%!IV6M!
M1+CD&A+@H.<#SJ.;\OAK#RIZO7^W3"UW<%[`=)<126/[P_>`Z:C5UG)?9[!K
MQJC_`%+2LAUM^VOO,K#K+T92VG$FH4E2"00?81KTG<2LEM7/806N82",B"*@
MCM5.!1RS'L3_`!/=?\,5_;-Z\Q^A7_;S_P"B?ZV*YW/\,=JZ^OJ+8S)P?>_`
M=UK0TIAR_P`%A]4E%16YV%]!"JCP/16R!^KKUS:FK2U=,<XP&"\CN&](_P#)
MOZM*]OZB6YC>=O;'8O8/[Q'NMB1EJ(S9YU+7>@AJ"@A->/*A=/UM?+5FFI*^
M\XWPN/(C9D6ZOYLO=[5OG-L):VX[-<JP5H)!Q?;.9!DJ1X+D(MZ_4.?TW2I7
M\NHS7:I`>M;9=VWY;:7Q?9B([Z8^U8T^EI]_O5_5V#\\_4B\Z%K7(><W\/\`
MF5&]V<09OWP?NG=W%KMDJZXI8"@*-4Q)3,13J4G]&ID+/#S-=9(,(JCK57S`
M//WCRW958WN('Q5]_45VGVVPO;_;^_XAA-HQ>[F^"T.2[5%;B=2'Z1YP-NI:
M"4KHIM)"E`J'MXG6*U>XN-2K;G.PMX((W1L#3JI@*84/!:E[,(4FY=H>"VZ'
M<'+3+N$&^1HMU:2%.1G';C-0AY"20"6R0H"OEK%<&DA[E?<M-+MK8T&A(=CP
M\1Q6=[;VU=J_:Y=9V3;W[BP<Z?EQ"FT8S?H;;CH<4KF<D(@,*?<?4KY0I2.4
M5)K4U&3S9),&A5+=EVW:G&2Z>'U&`</\M3589Q3(,*>[P\+OVT$5^Q81.S^S
M_NW"<065-1I+[+,AL-E2BA"RMP!)/!)IP\-22#Y7BSHM4@FB_P"68ZW%&&1M
M.PD5^ON7T;:JEW*FB*J=YMWL8V3P>?FF2ER44*3%L5BC4,NYSWN#$2.GB2I9
M\30\J:J\M<V,+S0*#N.X1V,)D?V`=+CP"I[8;:#*7[U<]^-[UB=NUFT,QHF/
M`GT6-V5PA;=K9:)Y2NE"Z37XN'CS*4N`R1AB(!8<"#B#VA5^TV,NLW=Q^*X8
M#H8W[(Z^/[2;[F[8X-.67'<?8:6HU)CJ6P*G^:VI(_S:T&]],^7;MVI]JT'_
M``%S/8P@>Q;0V\E;^\L6S&T,S9;+8HVU(<;;3XT2E9`'^37B^^B;%<2,;D'$
M#L!6PM-0"M?VG;W;M#W19M$>7/CMH7+9=<<?Z14`0%I4I24D^-"->R-L],N7
MH&-D%JUQ(!\1<\9<'$CV+777\CB6ZLE93##$5EN/&9;CL-#E:9:2$(2/8$B@
M&M^@@C@8(XVAK1D```.P#`*.23B5Y=95\31%T&]ZLV-;>\B5<IKG1A6YW%Y4
MQZA5R-,LQW'%4%2:)23PU90"L:ZGYE>&;MJ.0T^X+3GU"MW]MLQV=PFQXAF-
MJRBX7G(8]WCM6N4U)*(<>+(0IQX-J);JIY*0%`$FOL.L5JQP<:A77..XV\UH
MQD;PXEU<#7"AS^E:#[);=>[5VFX>Y!;;%UGIN]PM33X)0KJ3I!:"@"G@L)J.
M/F-5._ONA;S.LPTS!I+`[%I<!@#B,\LU?<H1Z+"/7D23W:BK`PW>"?\`C$F-
MFLE+,-Y/(RXA@($9Y"C4+"054/@:UH1^77GGD[U>N/S[XMZ>&QD4!#-/EO!Q
M#@!JH<C6M"!EBMWN+`:08\_>HGNY?\<R"]07["I$IQB.47"X-I*4NDD=-/$`
MJ*17C[Z>6M2]6]^VO=[^)]@0]S6D/>!0.Q\(Q`KI%<>L"N"D6$3XVG4M'8Q%
ME0<&M,2:")3-J2EU"O%)Z=0D^](X:]&\M6LUKR]!%-\[8!4',>'+N&'<JB9P
M=*2,JJAMB?XGNO\`ABO[9O70OH5_V\_^B?ZV*SW/\,=JK[ZAF"#+.WZ9D##!
M=N&WUTBWAM:150C.J])*'ZH2\%G]37K&U=1_:NNN<+3SK$N&;"#W9'WU[EU?
M=KEFO&\G<5M';[TO\0@X2S%?=*A\+=MQULNQFU>-070A']+4R8AC#3I6B["Q
M]]?Q!^(93Z&8CZ@N\/N/_P#06\O_`&=>/^$<U7Q?..U=H[U_L9ON.]RZ\OI:
M??[U?U=@_//U*O.A:=R'G-_#_F5&]V4M.$]\'[UW="T6R+=<4OREA)^*)%9B
M)<4GVT,=8X>8IK)!C%3M57S`?(WCS'958[N`'P5__48W2VZR_;[;ZP8IFEHR
M6[F^"[KAVN4W++<(Q'FPZXIDJ2BJG$@!1!/LX'6*U8X.-0K;G.^@G@C;&\..
MJN!KA0\%;FQ>;W/;;Z?47.;*PF1=\:L-_EVQ"T\R`^+I,2VM2?-*%*"B/,#7
M"5NJ6BL]HN76VR"1N;6NIVZBL4]GV.[.;H9KG^?]QV80;M?;06)\*VY//2PS
M/6\7%2)CZGEH#X:*4I#5>45XI(Y1J1.7-`#`M8Y<CM;N62:]>"X8@.-`>)-<
MZ<%";MD.'95WOX[?-OU1EX;)W#QQJPKA,"-&4U&>AL*++02@)05MJY:`5''S
MUR`(BQSH5$DEBEWEKHJ:/,92@H,"!@OH9U5KN%-$6"MM+>]W([]9/O+DJ#(V
MWV6NLG&=G;(X*L/W2.H"==EI/!2@H#IGR^'S;U(<?+;I&9S6K63#N5XZX?\`
MAQ$M8.L9N^'=]E;UU'6TJ!Y]N=@>V%K3=LYR6)8F'CR08KBBN7+<)H&HL5L*
M>?620`EM!.N36%V2BW=[#:MU2N`]Y[!F>Y8+])D^0REW?((\O;[&9CKDB%CB
MRE&3W!I:BIM4D#G3:V5`UH>:01X!OYM>4MUV#9.5)7S;DYMW>.<7,MV'^U'4
MU!F=F[[F%>!&*L8;B\W(#0###Q/XKNP9,'7B[L78EC5NLMILL"!86&(UO::2
MIMMA16"5"I6I:E*4M2CQ*E**E'B23KU%:7++B)KVN!!:#X2*9=%.C@HS86Q#
M2T4`7/:DKDFB)HBZ%.\MII_O14P^TA]A^5BC;[+B0I"T+;C)4E234$$&A!U9
M0?A+JCF0`[O0\6^X+L0OGT^^W"]Y&[D(L=VLS,A[KRL<MD]3%N6HFJ@&RA3C
M:3]EMQ('Z(&HHN7@46XR\I6$DFO21U`X?J[BMDV>SVO'[3;;%9(+-LL]GC-0
M[9;HZ>1IAAE(0VVA(\`E(`U@)KBMCCC;&T,:*`"@'4HCD.V>)Y+*7/F0W(LY
MWB_*B+Z2G#[5BA23[Z5UH',/IKLN]S&>:,MD.;F'27=;A0M)ZZ5ZU-BO)(Q0
M'#K7@LFU6'V*4U.9ANSI3"@IAR8YU`A0\%!`"4U'E4:C[)Z6;%M4S9V1ND>W
M$&0ZJ'B&@!M>%0:="^R7LL@I6@ZE8CC:76W&E_(XDI53V$4.NPY(Q(TM.1%/
MI44&BAF-;?X[B<Q^?9VY")$ADL.%UXN#D*@K@#YU2-:;RWR#M?+\[I[0.#W-
MTG4[4*5!R[0%(FNGRBCES&4XU:,RQN_8G?XWK+)DD"1;;K&!*2MB2V6UA*AQ
M2:*X$>!XZW9I(-0H,\#9XW1OQ:X$'L*H_9OM7VCV*OURR7`K?<6KO=('X;(D
MW":N7RQRXAU24!8`25*;34^[61\SGBA59MVQ6M@\OB!J13$]'Z!79EV+VK-L
M7R#$+ZEU=FR:WR+;=$,.%IPL26RVX$+'%)Y5&AUC::&H5E<0-GC=&_Y7`@]A
M55;+=N6VFP:LB7M[&N,<Y0(J;KZ^8N740^KTN3G`Y?OE5IXZYOE<_-0-MV>W
MV\N,(/BI6IX5^*]7>[MEVKW^5:I.=6^8U=[*VIBW7ZUR/32TL+5S%E2BEQ"T
M<WQ`*2:&M*5-?L<KF9+CN>R6VXT,H-1D1@57D7L4[=XF%R<):QR>8T^:Q/N-
M^,U?XI(7&"PTA4D`<K8ZA)0A*4DT)%1KE^8?6JBCE>Q$7E:32M:UQ^GAU*^\
M)VGPK`MN(VU-GMZY>%1HTR&JV7)PRBZQ.<==D-NK7Q4%%Y0H?+AK&YY<=72K
M2VV^&W@\AHJS$4..=2?>LMH^G3VWIN_XFN%D+T/J]5./KNBO1@5KR5#8?Y?+
M[VOOUE_-/HJ,<GV`?JHZG"N'NK[5.U=E&P3>=6K<&V8_-L-YL<RWS[5"MDU<
M:"R];`T&"F,D%-"6@5_:-2>).N/GOI12O_6K(3"9K2"""*&@\-*8=RUEK"K]
M5/O;F]\VWVXO.<6&PR<FD8W(M\NXV6&GFD/6Y,UD3^D`#\28Q<4#Y4J>&N<;
M0XT*@;G<OMH#*QNK202!PJ-7LJLDX7WK=L>+6(VC;S'\L?D7*;,N@PFV69YZ
M4F9/>5(D!(+A:`4ZLFB7"D5X<.&LSH'G-4%MS+M\;-,+7$DDZ0,:G$]-/:I6
M<^[M=Z/[MM[M[%V`Q.13GS3-:2KRIM0^:-;$BB%4-1U$D?SAKCI8S,U*D?FM
MRO<(8Q"W[3\7=S?B.]6IMKVS85@MS=S"_P!RN>Y>Y\QLIG;D9&^I^<@JKS""
MBI1#3QH`U\0'#FU@N?[\9C-0TBGA):>YPH1V@JPL=GBMG^:XF23[3L3W#(?I
MBK+7M3@;BUN.653CCBBIQQ<J2I2E'B227:DG77C_`$JY<>XN=;$DXDF24DGK
M\:V'\]-Q]@7.V##L<Q=R2]8[?Z)R6E*'SU77.9*22!1Q:@/'RU>[#R?M>Q/>
M^QBT%X`=XG.J!E\SG>Q8I;A\OS&JD^MF6%-$31%1.8=M&R6>YH-PLLPAN[9@
M%Q'!>%3)K1YH(2(YZ;3Z&_@"!^CQ\ZZR-E<!0'!5=QLMI<2^=(RK\,:GH[Z*
M]M8U:)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBAV/?[=+_A[Y3_`,I^
M_P#F/WON_P!.N14>+,_+W*8ZXJ0FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
2:(FB)HB:(FB)HB:(FB)HB__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
